Skip to main content
Fig. 7 | Alzheimer's Research & Therapy

Fig. 7

From: Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Fig. 7

Imaging, biomarker, and cognitive effects during and after treatment with lecanemab in the study 201 core and gap period for A amyloid PET SUVr, B amyloid Centiloid, C plasma Aβ42/40 ratio (standardized value), D p-tau181 (standardized value), E CDR-SB, F ADCOMS, and G ADAS-cog. F/up = 90-day follow-up period following study 201 core

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193